Titre The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Protocole ID COG-APEC14B1
ClinicalTrials.gov ID NCT02402244
Type(s) de cancer Pédiatrique divers
Phase
Institution CENTRE UNIVERSITAIRE DE SANTE MCGILL
   HOPITAL DE MONTREAL POUR ENFANTS
      1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville Montréal
Investigateur(trice) principal(e) Dre Sharon Abish
Coordonnateur(trice) Katia Pamphile
 514-412-4400 poste 22592

Margaret Hin-Chan
 514-412-4400 poste 23543
Statut Actif en recrutement
Critètes d'éligibilité
  • Enrollment can occur at any time after disease presentation including at time of disease progression or recurrence; for patients who are to be enrolled on COG therapeutic studies, enrollment on APEC14B1 must occur prior to enrollment onto the therapeutic trial
  • Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:
  • All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant)
  • All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
  • Other benign/borderline conditions including:
  • Mesoblastic nephroma
  • Teratomas
  • Myeloproliferative diseases including transient myeloproliferative disease
  • Langerhan cell histiocytosis
  • Lymphoproliferative diseases
  • Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network (NCTN) ) therapeutic study, for whom there is a higher upper age limit
  • All patients or their parents or legally authorized representatives must sign a written informed consent; parents will be asked to sign a separate consent for their own biospecimen submission
Critètes d'exclusion